Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter- and intra-cellular communication, which regulates fundamental cell functions such as growth, survival, and differentiation. The MAPK pathway also integrates signals from complex intracellular networks in performing cellular functions. Despite the initial discovery of the core elements of the MAPK pathways nearly four decades ago, additional findings continue to make a thorough understanding of the molecular mechanisms involved in the regulation of this pathway challenging. Considerable effort has been focused on the regulation of RAF, especially after the discovery of drug resistance and paradoxical activation upon inhibitor binding to the kinase. RAF activity is regulated by phosphorylation and conformation-dependent regulation, including auto-inhibition and dimerization. In this review, we summarize the recent major findings in the study of the RAS/RAF/MEK/ERK signaling cascade, particularly with respect to the impact on clinical cancer therapy.

[1]  M. Shibuya,et al.  Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1 , 2003, Nature Cell Biology.

[2]  U. Rapp,et al.  Craf-1 protein kinase is essential for mouse development , 1998, Mechanisms of Development.

[3]  C. Pritchard,et al.  The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. , 2012, Genes & development.

[4]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[5]  C. Pritchard,et al.  Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene , 1996, Current Biology.

[6]  H. Yao,et al.  cAMP Activates MAP Kinase and Elk-1 through a B-Raf- and Rap1-Dependent Pathway , 1997, Cell.

[7]  J. Otto,et al.  Targeted Inactivation of the Isoprenylcysteine Carboxyl Methyltransferase Gene Causes Mislocalization of K-Ras in Mammalian Cells* , 2000, The Journal of Biological Chemistry.

[8]  J. Rine,et al.  Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis , 1997, Science.

[9]  U. Rapp,et al.  Generation of new mouse sarcoma viruses in cell culture. , 1978, Science.

[10]  Boris N. Kholodenko,et al.  Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling , 2014, Nature Cell Biology.

[11]  Christof Fellmann,et al.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. , 2014, Cancer cell.

[12]  C. Der,et al.  Ras history , 2010, Small GTPases.

[13]  J. Desai,et al.  Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. , 2019, Journal of Clinical Oncology.

[14]  K. Xia,et al.  Interaction of the protein kinase Raf-1 with 14-3-3 proteins. , 1994, Science.

[15]  T. Veenstra,et al.  Protein Phosphatase 2A Positively Regulates Ras Signaling by Dephosphorylating KSR1 and Raf-1 on Critical 14-3-3 Binding Sites , 2003, Current Biology.

[16]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[17]  E. Castellano,et al.  Functional specificity of ras isoforms: so similar but so different. , 2011, Genes & cancer.

[18]  D. Cacchiarelli,et al.  Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. , 2016, Cell reports.

[19]  R. Stephens,et al.  KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis , 2019, Proceedings of the National Academy of Sciences.

[20]  Susan S. Taylor,et al.  Kinase Regulation by Hydrophobic Spine Assembly in Cancer , 2014, Molecular and Cellular Biology.

[21]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[22]  K. Flaherty,et al.  BRAF, a target in melanoma , 2010, Cancer.

[23]  T. Bonner,et al.  Characterization of murine A-raf, a new oncogene related to the v-raf oncogene , 1986, Molecular and cellular biology.

[24]  Ying Cheng,et al.  Current Development Status of MEK Inhibitors , 2017, Molecules.

[25]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[26]  X. F. Zhang,et al.  Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues , 1994, Molecular and cellular biology.

[27]  Frank McCormick,et al.  ras GTPase activating protein: Signal transmitter and signal terminator , 1989, Cell.

[28]  Raf-1 and B-Raf promote protein kinase C theta interaction with BAD. , 2007, Cellular signalling.

[29]  T. Veenstra,et al.  CK2 Is a Component of the KSR1 Scaffold Complex that Contributes to Raf Kinase Activation , 2007, Current Biology.

[30]  M. Reth,et al.  Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf , 2003, Oncogene.

[31]  U. Rapp,et al.  Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase* , 2011, The Journal of Biological Chemistry.

[32]  Jiancheng Hu,et al.  The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants , 2018, bioRxiv.

[33]  T. Kawabe,et al.  Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor κB Pathway and Cellular Transformation , 2004, Cancer Research.

[34]  T. Tan,et al.  DUSPs, to MAP kinases and beyond , 2012, Cell & Bioscience.

[35]  P. Casey,et al.  Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release. , 1995, Biochemistry.

[36]  M. Wigler,et al.  Complex formation between RAS and RAF and other protein kinases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Yong Zhou,et al.  Ras nanoclusters: Versatile lipid-based signaling platforms. , 2015, Biochimica et biophysica acta.

[38]  Philippe P Roux,et al.  RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.

[39]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.

[40]  J. Troppmair,et al.  Activation of NF-κB by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade , 1998, Oncogene.

[41]  W. Kolch,et al.  The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. , 2009, Cellular signalling.

[42]  P. J. Belshaw,et al.  Oligomerization activates c-Raf-1 through a Ras-dependent mechanism , 1996, Nature.

[43]  M. Therrien,et al.  Regulation of RAF protein kinases in ERK signalling , 2015, Nature Reviews Molecular Cell Biology.

[44]  Yoichi Matsubara,et al.  Recent advances in RASopathies , 2015, Journal of Human Genetics.

[45]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[46]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[47]  N. Perrimon,et al.  Requirement of the Drosophila raf homologue for torso function , 1989, Nature.

[48]  F H Reynolds,et al.  Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Der,et al.  M-Ras/R-Ras3, a Transforming Ras Protein Regulated by Sos1, GRF1, and p120 Ras GTPase-activating Protein, Interacts with the Putative Ras Effector AF6* , 1999, The Journal of Biological Chemistry.

[50]  G. Guy,et al.  Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf* , 2002, The Journal of Biological Chemistry.

[51]  P. Worley,et al.  Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells , 2002, Oncogene.

[52]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[53]  P. Casey,et al.  Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer , 2017, Molecular Cancer Therapeutics.

[54]  Paul W. Sternberg,et al.  C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation , 1993, Nature.

[55]  D. Fry,et al.  Chemical shift assignments and folding topology of the Ras-binding domain of human Raf-1 as determined by heteronuclear three-dimensional NMR spectroscopy. , 1994, Biochemistry.

[56]  D. Bar-Sagi,et al.  Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2 , 1996, Molecular and cellular biology.

[57]  Laura M. Heiser,et al.  Regulation of the Raf–MEK–ERK pathway by protein phosphatase 5 , 2006, Nature Cell Biology.

[58]  Susan S. Taylor,et al.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.

[59]  Peng-Fei Wang,et al.  A patent review of BRAF inhibitors: 2013-2018 , 2019, Expert opinion on therapeutic patents.

[60]  W. Kolch,et al.  Negative regulation of Raf-1 by phosphorylation of serine 621 , 1996, Molecular and cellular biology.

[61]  Min Han,et al.  The C. elegans ksr-1 gene encodes a novel raf-related kinase involved in Ras-mediated signal transduction , 1995, Cell.

[62]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[63]  B. Cochran,et al.  p50cdc37 Acting in Concert with Hsp90 Is Required for Raf-1 Function , 1999, Molecular and Cellular Biology.

[64]  B. Calabretta,et al.  Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. , 1999, Cancer research.

[65]  Robert G. Parton,et al.  Direct visualization of Ras proteins in spatially distinct cell surface microdomains , 2003, The Journal of cell biology.

[66]  Walter Kolch,et al.  Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation , 2015, Angewandte Chemie.

[67]  L. Decoster,et al.  Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib , 2016, Oncotarget.

[68]  J. Hancock,et al.  Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions , 2001, Oncogene.

[69]  Jie Zhang,et al.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  M. Therrien,et al.  RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition , 2017, Nature Communications.

[71]  T. Sturgill,et al.  Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. , 1988, The Journal of biological chemistry.

[72]  Nancy Y. Ip,et al.  ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF , 1991, Cell.

[73]  D. Morrison,et al.  Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner. , 1994, The Journal of biological chemistry.

[74]  G. Piazza,et al.  The RAS-Effector Interaction as a Drug Target. , 2017, Cancer research.

[75]  Abran Q. Costales,et al.  Discovery of RAF 265 : A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma , 2015 .

[76]  W. Min,et al.  Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. , 2007, Cancer research.

[77]  L. Ambrosio,et al.  Drosophila Raf's N Terminus Contains a Novel Conserved Region and Can Contribute to Torso RTK Signaling , 2010, Genetics.

[78]  R. Stephens,et al.  Autoregulation of the Raf-1 serine/threonine kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Frost,et al.  p21 activated kinase 5 activates Raf‐1 and targets it to mitochondria , 2008, Journal of cellular biochemistry.

[80]  Susan S. Taylor,et al.  Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF , 2011, Proceedings of the National Academy of Sciences.

[81]  N. Hacohen,et al.  sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways , 1998, Cell.

[82]  S. Sebti Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. , 2005, Cancer cell.

[83]  Tomoyasu Ishikawa,et al.  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.

[84]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[85]  M. Philips,et al.  Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras Published, JLR Papers in Press, March 16, 2006. , 2006, Journal of Lipid Research.

[86]  S. Welsh,et al.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma , 2015, Therapeutic advances in medical oncology.

[87]  Mei Wang,et al.  Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth , 2010, Oncogene.

[88]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[89]  Larissa V Furtado,et al.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. , 2014, Blood.

[90]  S. O’Brien,et al.  The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. , 1984, Science.

[91]  Weiru Wang,et al.  Ras inhibition via direct Ras binding--is there a path forward? , 2012, Bioorganic & medicinal chemistry letters.

[92]  J. Rojas,et al.  H-Ras-specific activation of NF-κB protects NIH 3T3 cells against stimulus-dependent apoptosis , 2003, Oncogene.

[93]  R. Nussinov,et al.  Mechanisms of Membrane Binding of Small GTPase K-Ras4B Farnesylated Hypervariable Region* , 2015, The Journal of Biological Chemistry.

[94]  Susan S. Taylor,et al.  Pseudokinases from a structural perspective. , 2013, Biochemical Society transactions.

[95]  V. Sondak,et al.  The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms , 2012, Clinical Cancer Research.

[96]  M. Barbacid,et al.  H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. , 2017, Cancer research.

[97]  M. H. Cobb,et al.  Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338 , 2000, Current Biology.

[98]  C. Pritchard,et al.  A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression , 2005, Oncogene.

[99]  K. Inouye,et al.  Formation of the Ras Dimer Is Essential for Raf-1 Activation* , 2000, The Journal of Biological Chemistry.

[100]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[101]  Kristina M. Ilieva,et al.  Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models , 2014, Molecular Cancer Therapeutics.

[102]  Stephen B. Long,et al.  Reaction path of protein farnesyltransferase at atomic resolution , 2002, Nature.

[103]  M. Barbacid,et al.  Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. , 2005, Cancer cell.

[104]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[105]  Nadinath B. Nillegoda,et al.  Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation , 2007, The Journal of cell biology.

[106]  P. Workman,et al.  Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. , 2005, Cancer research.

[107]  G. Tzivion,et al.  Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.

[108]  A. Brunet,et al.  B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222. , 1995, Oncogene.

[109]  W. Kolch,et al.  Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.

[110]  Timothy Travers,et al.  Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain , 2018, Scientific Reports.

[111]  A. Ashworth,et al.  Identification of the sites in MAP kinase kinase‐1 phosphorylated by p74raf‐1. , 1994, The EMBO journal.

[112]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[113]  Susan S. Taylor,et al.  Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers , 2013, Cell.

[114]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[115]  E. Krebs,et al.  Identification of multiple epidermal growth factor-stimulated protein serine/threonine kinases from Swiss 3T3 cells. , 1990, The Journal of biological chemistry.

[116]  Manuela Baccarini,et al.  A balance between Raf-1 and Fas expression sets the pace of erythroid differentiation. , 2006, Blood.

[117]  S. Ficarro,et al.  Architecture of autoinhibited and active BRAF/MEK1/14-3-3 complexes , 2019, Nature.

[118]  Abran Q. Costales,et al.  Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. , 2015, ACS medicinal chemistry letters.

[119]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[120]  J. Hancock,et al.  Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.

[121]  C. Pritchard,et al.  Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. , 2005, Cancer research.

[122]  S. Elledge,et al.  Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.

[123]  W. Sellers,et al.  Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. , 2020, Journal of medicinal chemistry.

[124]  Roland L. Dunbrack,et al.  Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors , 2014, Journal of medicinal chemistry.

[125]  S. Subramaniam,et al.  Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases , 2019, Science.

[126]  R. Thapar,et al.  NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. , 2004, Journal of molecular biology.

[127]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[128]  S. Sebti,et al.  Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.

[129]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[130]  A. Balmain,et al.  A model for RAS mutation patterns in cancers: finding the sweet spot , 2018, Nature Reviews Cancer.

[131]  Robert G Parton,et al.  H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[132]  M. Barbacid,et al.  RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling , 2018, Nature Medicine.

[133]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[134]  P. Casey,et al.  GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. , 2007, The Journal of clinical investigation.

[135]  A. King,et al.  Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling , 1997, Molecular and cellular biology.

[136]  M. Atkins,et al.  Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma , 2006, Clinical Cancer Research.

[137]  Tianhai Tian,et al.  Plasma membrane nanoswitches generate high-fidelity Ras signal transduction , 2007, Nature Cell Biology.

[138]  M. Vitale,et al.  Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation , 2012, Cell cycle.

[139]  M. Barbacid,et al.  c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. , 2018, Cancer cell.

[140]  H. Beug,et al.  Raf-1 Antagonizes Erythroid Differentiation by Restraining Caspase Activation , 2002, The Journal of experimental medicine.

[141]  F. McCormick,et al.  RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. , 2013, Cancer cell.

[142]  P. Casey,et al.  An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo , 2014, Cancer biology & therapy.

[143]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[144]  D. Morrison,et al.  Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro , 1995, Molecular and cellular biology.

[145]  Giulio Superti‐Furga,et al.  Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.

[146]  Marc Therrien,et al.  Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation , 2014, Nature Structural &Molecular Biology.

[147]  E. Wagner,et al.  Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene , 2001, The EMBO journal.

[148]  W. Fantl,et al.  Activation of Raf-1 by 14-3-3 proteins , 1994, Nature.

[149]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[150]  H. Horvitz,et al.  The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans , 1995, Cell.

[151]  J. Yap,et al.  Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.

[152]  M. Baccarini,et al.  Raf-1 addiction in Ras-induced skin carcinogenesis. , 2009, Cancer cell.

[153]  W. Kolch,et al.  Tumor and Stem Cell Biology Heterogeneous Nuclear Ribonucleoprotein H Blocks Mst2-mediated Apoptosis in Cancer Cells by Regulating A-raf Transcription , 2022 .

[154]  C. Crews,et al.  Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[155]  How to fool a wonder drug: truncate and dimerize. , 2012, Cancer cell.

[156]  R. Zahedi,et al.  Positive Regulation of A-RAF by Phosphorylation of Isoform-specific Hinge Segment and Identification of Novel Phosphorylation Sites* , 2008, Journal of Biological Chemistry.

[157]  D. Morrison,et al.  Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. , 2016, Molecular cell.

[158]  Jing Chen,et al.  Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[159]  G. Ladds,et al.  Ras activation revisited: role of GEF and GAP systems , 2015, Biological chemistry.

[160]  R. Lurz,et al.  Two unrelated cell‐derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. , 1983, The EMBO journal.

[161]  C. Pritchard,et al.  A new mode of RAF autoregulation: a further complication in the inhibitor paradox. , 2013, Cancer cell.

[162]  Yuri K Peterson,et al.  A Novel Protein Geranylgeranyltransferase-I Inhibitor with High Potency, Selectivity, and Cellular Activity* , 2006, Journal of Biological Chemistry.

[163]  KL Pennington,et al.  The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein–protein interactions , 2018, Oncogene.

[164]  P. Casey,et al.  Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.

[165]  W. Kolch,et al.  Spatial regulation of ARAF controls the MST2-Hippo pathway , 2017, Small GTPases.

[166]  C. Marshall,et al.  Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation. , 1995, The EMBO journal.

[167]  D. Adams,et al.  Synthetic lethality: emerging targets and opportunities in melanoma , 2017, Pigment cell & melanoma research.

[168]  R. Gibbs,et al.  S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase. , 2012, ACS medicinal chemistry letters.

[169]  D. Morrison,et al.  The complexity of Raf-1 regulation. , 1997, Current opinion in cell biology.

[170]  M. Weber,et al.  Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.

[171]  M. Bergo,et al.  Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. , 2008, Blood.

[172]  Michael B Yaffe,et al.  How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesis , 2002, FEBS letters.

[173]  S. Cook,et al.  Inhibition by cAMP of Ras-dependent activation of Raf. , 1993, Science.

[174]  K. Moelling,et al.  Serine- and threonine-specific protein kinase activities of purified gag–mil and gag–raf proteins , 1984, Nature.

[175]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[176]  R. Murphy,et al.  Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition , 2017, The EMBO journal.

[177]  T. Haystead,et al.  Functional expression of a MAP kinase kinase in COS cells and recognition by an anti‐STE7/byrl antibody , 1993, FEBS letters.

[178]  Marc Therrien,et al.  MEK drives BRAF activation through allosteric control of KSR proteins , 2018, Nature.

[179]  D J Glass,et al.  Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. , 1999, Science.

[180]  F. McCormick,et al.  Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. , 1994, Science.

[181]  T. Sturgill,et al.  Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[182]  M. Nikiforova,et al.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.

[183]  Carol L. Williams A new signaling paradigm to control the prenylation and trafficking of small GTPases , 2013, Cell cycle.

[184]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[185]  C. Pritchard,et al.  MEK kinase activity is not necessary for Raf‐1 function , 2001, The EMBO journal.

[186]  M. Farrar,et al.  Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization , 1996, Nature.

[187]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[188]  S. Wiese,et al.  B- and C-RAF Display Essential Differences in Their Binding to Ras , 2007, Journal of Biological Chemistry.

[189]  Shinichi Suzuki,et al.  BRAF mutations in papillary carcinomas of the thyroid , 2003, Oncogene.

[190]  Jonathan A. Cooper,et al.  A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[191]  K. Xia,et al.  The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[192]  W. Hahn,et al.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.

[193]  Aaron N. Chang,et al.  Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions , 2017, Nature Methods.

[194]  P. Casey,et al.  High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors* , 2003, Journal of Biological Chemistry.

[195]  P. Casey,et al.  Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. , 2004, The Journal of clinical investigation.

[196]  David T. W. Jones,et al.  Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma , 2011, Acta Neuropathologica.

[197]  A. King,et al.  The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338 , 1998, Nature.

[198]  N. Tsuchida,et al.  RAS Mutations in Human Cancers: Roles in Precision Medicine. , 2019, Seminars in cancer biology.

[199]  O. Carugo,et al.  From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-α kinase activity , 2009, The Journal of cell biology.

[200]  D. Morrison,et al.  Identification of the major phosphorylation sites of the Raf-1 kinase. , 1993, The Journal of biological chemistry.

[201]  J. Homsi,et al.  Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma , 2017, Case reports in oncological medicine.

[202]  B. Neyns,et al.  Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. , 2012, Melanoma research.

[203]  R. Nussinov,et al.  Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. , 2015, Structure.

[204]  A. Resnick,et al.  CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles , 2017, Oncogene.

[205]  D. Bar-Sagi,et al.  Regulating the regulator: post-translational modification of RAS , 2011, Nature Reviews Molecular Cell Biology.

[206]  D. Elder,et al.  CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations , 2009, Oncogene.

[207]  Y. Ueyama,et al.  B-raf, a new member of the raf family, is activated by DNA rearrangement , 1988, Molecular and cellular biology.

[208]  T. Roberts,et al.  Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[209]  Marc Therrien,et al.  A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.

[210]  D. Hardie,et al.  Identification of Raf‐1 Ser621 kinase activity from NIH 3T3 cells as AMP‐activated protein kinase , 1997, FEBS letters.

[211]  Walter Kolch,et al.  Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.

[212]  J. Miyazaki,et al.  Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. , 2004, The Journal of clinical investigation.

[213]  N. Dumaz,et al.  Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles , 2016, Oncotarget.

[214]  T. Wirth,et al.  Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[215]  Christopher J. Staples,et al.  Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter , 2008, The Biochemical journal.

[216]  C. Der,et al.  KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment , 2016, Cancers.

[217]  Alfred Wittinghofer,et al.  Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction , 2008, Biological chemistry.

[218]  R. Marais,et al.  S338 Phosphorylation of Raf-1 Is Independent of Phosphatidylinositol 3-Kinase and Pak3 , 2001, Molecular and Cellular Biology.

[219]  J. Feramisco,et al.  Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins , 1984, Nature.

[220]  O. Abdel-Wahab,et al.  BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.

[221]  M. Baccarini,et al.  Knock‐in(g) RAF for a loop , 2016, The EMBO journal.

[222]  M. Digilio,et al.  Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum , 2009, Human mutation.

[223]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[224]  D. K. Treiber,et al.  Ins and outs of kinase DFG motifs. , 2013, Chemistry & biology.

[225]  E. Petricoin,et al.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer , 2019, Nature Medicine.

[226]  A. Wittinghofer,et al.  The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue , 1995, Nature.

[227]  Ariana Peck,et al.  Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. , 2014, Cancer cell.

[228]  L. Chin,et al.  The Brothers RAF , 2010, Cell.

[229]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[230]  A. Baldwin,et al.  Oncogenic Ras Enhances NF-κB Transcriptional Activity through Raf-dependent and Raf-independent Mitogen-activated Protein Kinase Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[231]  T. Bonner,et al.  The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. , 1987, Nucleic acids research.

[232]  C. Fuchs,et al.  Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. , 2002, Molecular cancer therapeutics.

[233]  W. Kolch,et al.  Raf-1 and B-Raf promote protein kinase C θ interaction with BAD , 2007 .

[234]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[235]  S. Mayor,et al.  GPI-anchored proteins are organized in submicron domains at the cell surface , 1998, Nature.

[236]  W. Kolch,et al.  Cyclic AMP-Dependent Kinase Regulates Raf-1 Kinase Mainly by Phosphorylation of Serine 259 , 2002, Molecular and Cellular Biology.

[237]  J. Hancock,et al.  Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.

[238]  U. Rapp,et al.  Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.

[239]  Nicolas Stransky,et al.  The landscape of kinase fusions in cancer , 2014, Nature Communications.

[240]  J. Frost,et al.  Phosphorylation of Raf-1 by p21-activated Kinase 1 and Src Regulates Raf-1 Autoinhibition* , 2003, The Journal of Biological Chemistry.

[241]  T. Bonner,et al.  Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611 , 1984, Nature.

[242]  P. Casey,et al.  The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein , 1991, Molecular and cellular biology.

[243]  C. Ottmann,et al.  Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling , 2010, Molecular and Cellular Biology.

[244]  Henry C. Chang,et al.  KSR, a novel protein kinase required for RAS signal transduction , 1995, Cell.

[245]  S. Braun,et al.  Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants , 2016, The EMBO journal.

[246]  Susan S. Taylor,et al.  Kinases and Pseudokinases: Lessons from RAF , 2014, Molecular and Cellular Biology.

[247]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[248]  P. Casey,et al.  Enzymatic modification of proteins with a geranylgeranyl isoprenoid. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[249]  J. Small,et al.  Raf-1 regulates Rho signaling and cell migration , 2005, The Journal of cell biology.

[250]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[251]  M. Pacher,et al.  Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association* , 2002, The Journal of Biological Chemistry.

[252]  T. Kawabe,et al.  Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.

[253]  Wei Cheng,et al.  Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. , 2016, Cancer letters.

[254]  T. Hunter,et al.  Cdc37: a protein kinase chaperone? , 1997, Trends in cell biology.

[255]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[256]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[257]  C. Kozak,et al.  A new oncogene, c-raf, is located on mouse chromosome 6 , 1984, Journal of virology.

[258]  J. Avruch,et al.  An intact Raf zinc finger is required for optimal binding to processed Ras and for ras-dependent Raf activation in situ , 1997, Molecular and cellular biology.

[259]  A. Eychène,et al.  Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. , 1996, Oncogene.

[260]  PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation , 2017, Molecular Cancer.

[261]  K. Guan,et al.  Positive and negative regulation of Raf kinase activity and function by phosphorylation , 2001, The EMBO journal.

[262]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[263]  A. Nishi,et al.  Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain* , 2015, The Journal of Biological Chemistry.

[264]  C. Der,et al.  RAS Mutations Are Not Created Equal. , 2019, Cancer discovery.

[265]  N. Rosen,et al.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[266]  K. Dutta,et al.  A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling , 2016, Cell.

[267]  T. Bonner,et al.  Structure and biological activity of human homologs of the raf/mil oncogene , 1985, Molecular and cellular biology.

[268]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[269]  P. Casey,et al.  Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. , 1998, Biochemistry.

[270]  D. Morrison,et al.  Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.

[271]  M. Baccarini,et al.  Raf-1 sets the threshold of Fas sensitivity by modulating Rok-α signaling , 2005, The Journal of cell biology.

[272]  John Calvin Reed,et al.  Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.

[273]  J. Troppmair,et al.  The ins and outs of Raf kinases. , 1994, Trends in biochemical sciences.

[274]  P. Casey,et al.  Post-prenylation-processing enzymes as new targets in oncogenesis , 2005, Nature Reviews Cancer.

[275]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[276]  S. Wiese,et al.  Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons , 2001, Nature Neuroscience.

[277]  P. Thompson,et al.  The Raf-1 serine-threonine kinase is a substrate for the p56lck protein tyrosine kinase in human T-cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[278]  R. Benz,et al.  Negative regulation of mitochondrial VDAC channels by C-Raf kinase , 2002, BMC Cell Biology.

[279]  T. Brummer,et al.  B-Raf activation loop phosphorylation revisited , 2016, Cell cycle.

[280]  C. Der,et al.  Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[281]  P. Casey,et al.  p21ras is modified by a farnesyl isoprenoid. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[282]  P. Casey,et al.  Protein prenylation: unique fats make their mark on biology , 2016, Nature Reviews Molecular Cell Biology.

[283]  C. Der,et al.  Elucidation of Binding Determinants and Functional Consequences of Ras/Raf-Cysteine-rich Domain Interactions* , 2000, The Journal of Biological Chemistry.

[284]  Zhongzhou Chen,et al.  Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis , 2018, Science Signaling.

[285]  A. Neri,et al.  Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP. , 1994, The Journal of biological chemistry.

[286]  P. Dent,et al.  Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. , 1993, Science.

[287]  J. Frost,et al.  B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms* , 2005, Journal of Biological Chemistry.

[288]  P. Allen,et al.  Interaction of 14-3-3 with Signaling Proteins Is Mediated by the Recognition of Phosphoserine , 1996, Cell.

[289]  M. Therrien,et al.  A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila. , 2006, Genes & development.

[290]  J. Field,et al.  p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association* , 2005, Journal of Biological Chemistry.

[291]  A. Sweet-Cordero,et al.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.

[292]  W. Kolch,et al.  Raf-1 protein kinase is required for growth of induced NIH/3T3 cells , 1991, Nature.

[293]  T. Haystead,et al.  Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. , 1992, Science.

[294]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[295]  A. von Deimling,et al.  Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.

[296]  Junfeng Xia,et al.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.

[297]  C. Der,et al.  Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*) , 1995, The Journal of Biological Chemistry.

[298]  P. Casey,et al.  A Small Molecule Inhibitor of Isoprenylcysteine Carboxymethyltransferase Induces Autophagic Cell Death in PC3 Prostate Cancer Cells*♦ , 2008, Journal of Biological Chemistry.

[299]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[300]  N. Kohl,et al.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.

[301]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[302]  D. Morrison,et al.  14-3-3 Proteins: diverse functions in cell proliferation and cancer progression. , 2011, Seminars in cell & developmental biology.

[303]  D. Morrison,et al.  Ras-Mediated Activation of the Raf Family Kinases. , 2019, Cold Spring Harbor perspectives in medicine.

[304]  Evert Bosdriesz,et al.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.

[305]  Jonathan A. Cooper,et al.  Identification of Residues in the Cysteine-rich Domain of Raf-1 That Control Ras Binding and Raf-1 Activity* , 1998, The Journal of Biological Chemistry.

[306]  R. Benz,et al.  Regulation of glycolysis by Raf protein serine/threonine kinases. , 2002, Advances in enzyme regulation.

[307]  Mark R. Smith,et al.  Requirement for c-ras proteins during viral oncogene transformation , 1986, Nature.

[308]  K.,et al.  KSR stimulates Raf-1 activity in a kinase-independent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[309]  Mark R. Smith,et al.  Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells , 1985, Nature.

[310]  Jiancheng Hu,et al.  The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho–Ser-621 in the C terminus of CRAF , 2018, The Journal of Biological Chemistry.

[311]  K. Guan,et al.  Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601 , 2000, The EMBO journal.

[312]  D. Tuveson,et al.  C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.

[313]  Alma L. Burlingame,et al.  A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK , 2011, Nature.

[314]  P. Casey,et al.  Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[315]  Susan S. Taylor,et al.  Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.

[316]  Christopher L. McClendon,et al.  A dynamic hydrophobic core orchestrates allostery in protein kinases , 2017, Science Advances.

[317]  T Takahashi,et al.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis , 2001, EMBO reports.

[318]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[319]  O. Ilkayeva,et al.  Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism , 2014, Oncogene.

[320]  A. Borczuk,et al.  Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. , 2010, Carcinogenesis.

[321]  H. Mott,et al.  The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.